ACOG
Alpha Cognition Inc. Common Stock
Price Chart
Latest Quote
$4.94
Current Price| Previous Close | $4.92 |
| Open | $4.77 |
| Day High | $5.44 |
| Day Low | $4.77 |
| Volume | 51,358 |
Stock Information
| Shares Outstanding | 21.74M |
| Cash Equivalents | $35.40M |
| Revenue | $7.43M |
| Net Income | $-19.47M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $107.41M |
| EPS (TTM) | $-1.38 |
| Exchange | NCM |
đ Custom Metrics & Score
Score: 14/42| Debt to Equity | 0.02 |
| Debt to Earnings | -0.06 |
| Current Ratio | 15.00 |
| Quick Ratio | 14.56 |
| Return on Equity | -35.30% |
| Avg FCF Growth | -5.43% |
| FCF Yield | -7.25% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $4.94 | 51,358 |
| 2026-01-30 | $4.84 | 18,800 |
| 2026-01-29 | $5.18 | 21,200 |
| 2026-01-28 | $5.37 | 111,800 |
| 2026-01-27 | $5.89 | 13,900 |
| 2026-01-26 | $5.89 | 16,900 |
| 2026-01-23 | $5.95 | 22,800 |
| 2026-01-22 | $5.70 | 32,200 |
| 2026-01-21 | $5.85 | 168,300 |
| 2026-01-20 | $5.58 | 133,100 |
| 2026-01-16 | $5.72 | 90,200 |
| 2026-01-15 | $5.82 | 66,500 |
| 2026-01-14 | $5.93 | 57,800 |
| 2026-01-13 | $6.02 | 88,200 |
| 2026-01-12 | $6.09 | 136,200 |
| 2026-01-09 | $6.53 | 57,500 |
| 2026-01-08 | $6.56 | 24,500 |
| 2026-01-07 | $6.50 | 44,300 |
| 2026-01-06 | $6.18 | 12,000 |
| 2026-01-05 | $6.17 | 22,900 |
About Alpha Cognition Inc. Common Stock
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
đ° Latest News
Hedge funds own 20% of Alpha Cognition Inc. (NASDAQ:ACOG) shares but individual investors control 53% of the company
Simply Wall St. âĸ 2026-01-06T14:19:52Z
Are Medical Stocks Lagging Alpha Cognition Inc. (ACOG) This Year?
Zacks âĸ 2025-12-05T14:40:03Z
Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2025-11-19T14:41:02Z
Here's Why We're Not Too Worried About Alpha Cognition's (NASDAQ:ACOG) Cash Burn Situation
Simply Wall St. âĸ 2025-11-16T13:09:34Z
Alpha Cognition Inc. (ACOG) Reports Q3 Loss, Tops Revenue Estimates
Zacks âĸ 2025-11-13T23:40:02Z
Insiders Rewarded With US$150k Addition To Investment As Alpha Cognition Stock Hits US$144m
Simply Wall St. âĸ 2025-09-09T10:25:58Z
Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates
Zacks âĸ 2025-08-14T22:55:02Z
Individual investors account for 40% of Alpha Cognition Inc.'s (NASDAQ:ACOG) ownership, while hedge funds account for 27%
Simply Wall St. âĸ 2025-07-30T13:56:49Z
What Makes Alpha Cognition Inc. (ACOG) a New Strong Buy Stock
Zacks âĸ 2025-07-04T16:00:03Z
Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year?
Zacks âĸ 2025-07-01T13:40:02Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $185,777 | $77,293 | $172,880 | $528,160 |
| Total Expenses | $10,911,910 | $9,617,813 | $13,465,624 | $11,568,728 |
| Other Income Expense | $-3,241,482 | $-4,075,356 | $1,521,881 | $-7,450,202 |
| Net Non Operating Interest Income Expense | $-483,473 | $-70,489 | $-170,955 | $-526,086 |
| Total Other Finance Cost | $459,360 | - | - | - |
| Interest Expense Non Operating | $185,777 | $77,293 | $172,880 | $528,160 |
| Operating Expense | $10,911,910 | $9,617,813 | $13,465,624 | $11,568,728 |
| Other Operating Expenses | $-463,881 | $-260,503 | $509,860 | $122,285 |
| Selling And Marketing Expense | $97,535 | $19,791 | $31,733 | $103,250 |
| General And Administrative Expense | $7,223,493 | $4,890,073 | $4,016,266 | $3,279,976 |
| Other Non Operating Income Expenses | - | - | - | $-1,404,200 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-14,636,865 | $-13,763,658 | $-12,114,698 | $-19,545,016 |
| Net Interest Income | $-483,473 | $-70,489 | $-170,955 | $-526,086 |
| Interest Income | $161,664 | $6,804 | $1,925 | $2,074 |
| Normalized Income | $-11,395,383 | $-9,688,302 | $-13,636,579 | $-12,094,814 |
| Net Income From Continuing And Discontinued Operation | $-14,636,865 | $-13,763,658 | $-12,114,698 | $-19,545,016 |
| Total Operating Income As Reported | $-11,860,655 | $-9,938,093 | - | - |
| Net Income Common Stockholders | $-14,636,865 | $-13,763,658 | $-12,114,698 | $-19,545,016 |
| Net Income | $-14,636,865 | $-13,763,658 | $-12,114,698 | $-19,545,016 |
| Net Income Including Noncontrolling Interests | $-14,636,865 | $-13,763,658 | $-12,114,698 | $-19,545,016 |
| Net Income Continuous Operations | $-14,636,865 | $-13,763,658 | $-12,114,698 | $-19,545,016 |
| Pretax Income | $-14,636,865 | $-13,763,658 | $-12,114,698 | $-19,545,016 |
| Special Income Charges | $-39,166 | $0 | $-5,506 | $-1,441,704 |
| Interest Income Non Operating | $161,664 | $6,804 | $1,925 | $2,074 |
| Operating Income | $-10,911,910 | $-9,617,813 | $-13,465,624 | $-11,568,728 |
| Depreciation Amortization Depletion Income Statement | $81,220 | $84,479 | $90,923 | $89,877 |
| Depreciation And Amortization In Income Statement | $81,220 | $84,479 | $90,923 | $89,877 |
| Amortization Of Intangibles Income Statement | $79,875 | $82,376 | $82,376 | $82,375 |
| Depreciation Income Statement | $1,345 | $2,103 | $8,547 | $7,502 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-2.02 | $-3.84 | $-4.50 | $-9.25 |
| Basic EPS | $-2.02 | $-3.84 | $-4.50 | $-9.25 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,128,386 | $-9,526,530 | $-13,372,776 | $-11,476,777 |
| Total Unusual Items | $-3,241,482 | $-4,075,356 | $1,521,881 | $-7,450,202 |
| Total Unusual Items Excluding Goodwill | $-3,241,482 | $-4,075,356 | $1,521,881 | $-7,450,202 |
| Reconciled Depreciation | $81,220 | $84,479 | $90,923 | $89,877 |
| EBITDA (Bullshit earnings) | $-14,369,868 | $-13,601,886 | $-11,850,895 | $-18,926,979 |
| EBIT | $-14,451,088 | $-13,686,365 | $-11,941,818 | $-19,016,856 |
| Diluted Average Shares | $7,247,864 | $3,585,440 | $2,718,887 | $2,133,322 |
| Basic Average Shares | $7,247,864 | $3,585,440 | $2,718,887 | $2,133,322 |
| Diluted NI Availto Com Stockholders | $-14,636,865 | $-13,763,658 | $-12,114,698 | $-19,545,016 |
| Impairment Of Capital Assets | $39,166 | $0 | $5,506 | $0 |
| Gain On Sale Of Security | $-3,202,316 | $-4,075,356 | $1,527,387 | $-6,008,498 |
| Provision For Doubtful Accounts | $55,000 | $0 | - | - |
| Amortization | $79,875 | $82,376 | $82,376 | $82,375 |
| Research And Development | $3,918,543 | $4,883,973 | $8,816,842 | $7,973,340 |
| Selling General And Administration | $7,321,028 | $4,909,864 | $4,047,999 | $3,383,226 |
| Other Gand A | $5,170,788 | $1,473,992 | $1,386,429 | $2,300,090 |
| Salaries And Wages | $2,052,705 | $3,416,081 | $2,629,837 | $979,886 |
| Other Special Charges | - | $18,489 | - | - |
| Restructuring And Mergern Acquisition | - | - | $0 | $1,441,704 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $41,050,076 | $-5,235,705 | $-1,934,563 | $8,332,829 |
| Total Assets | $50,736,938 | $2,452,170 | $2,950,951 | $12,880,388 |
| Total Non Current Assets | $485,760 | $533,731 | $618,210 | $709,763 |
| Other Non Current Assets | $45,714 | - | - | - |
| Goodwill And Other Intangible Assets | $412,969 | $532,010 | $614,386 | $696,762 |
| Other Intangible Assets | $412,969 | $532,010 | $614,386 | $696,762 |
| Current Assets | $50,251,178 | $1,918,439 | $2,332,741 | $12,170,625 |
| Restricted Cash | $17,872 | $90,413 | $0 | - |
| Prepaid Assets | $818,537 | $266,280 | $249,045 | $868,832 |
| Inventory | $615,133 | $0 | - | - |
| Receivables | $253,426 | $157,586 | $0 | $0 |
| Other Receivables | $253,426 | $100,036 | - | - |
| Loans Receivable | $0 | $57,550 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $48,546,210 | $1,404,160 | $2,083,696 | $11,301,793 |
| Cash And Cash Equivalents | $48,546,210 | $1,404,160 | $2,083,696 | $11,301,793 |
| Other Current Assets | - | $366,316 | $249,045 | - |
| Cash Financial | - | $1,404,160 | $2,083,696 | $11,301,793 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $911,463 | $1,211,463 | $1,211,463 | $1,075,820 |
| Current Debt And Capital Lease Obligation | $911,463 | $1,211,463 | $1,211,463 | $1,075,820 |
| Current Debt | $911,463 | $1,211,463 | $1,211,463 | $1,075,820 |
| Other Current Borrowings | $911,463 | $1,211,463 | $1,211,463 | $1,075,820 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $9,273,893 | $7,155,865 | $4,271,128 | $3,850,797 |
| Total Non Current Liabilities Net Minority Interest | $5,923,141 | $4,539,872 | $214,284 | $2,048,127 |
| Other Non Current Liabilities | $102,783 | $84,125 | $8,295 | - |
| Derivative Product Liabilities | $5,820,358 | $4,455,747 | $205,989 | $2,048,127 |
| Current Liabilities | $3,350,752 | $2,615,993 | $4,056,844 | $1,802,670 |
| Current Deferred Liabilities | $0 | $10,413 | $0 | - |
| Payables And Accrued Expenses | $2,439,289 | $1,394,117 | $2,294,721 | $726,850 |
| Payables | $872,676 | $475,553 | $2,016,057 | $454,992 |
| Accounts Payable | $872,676 | $475,553 | $2,016,057 | $454,992 |
| Current Notes Payable | - | $1,220,372 | $1,211,463 | $1,075,820 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $41,462,983 | $-4,703,757 | $-1,320,177 | $9,029,529 |
| Preferred Stock Equity | $62 | $62 | $62 | $62 |
| Total Equity Gross Minority Interest | $41,463,045 | $-4,703,695 | $-1,320,177 | $9,029,591 |
| Stockholders Equity | $41,463,045 | $-4,703,695 | $-1,320,177 | $9,029,591 |
| Gains Losses Not Affecting Retained Earnings | $-104,301 | $-104,301 | $8,407,731 | $7,051,718 |
| Other Equity Adjustments | $-104,301 | $-104,301 | $8,407,731 | $7,051,718 |
| Retained Earnings | $-76,285,038 | $-61,648,173 | $-49,986,851 | $-38,033,903 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $16,019,787 | $4,728,359 | $2,720,938 | $2,704,277 |
| Share Issued | $16,019,787 | $4,728,359 | $2,720,938 | $2,704,277 |
| Tangible Book Value | $41,050,014 | $-5,235,767 | $-1,934,563 | $8,332,767 |
| Invested Capital | $42,374,446 | $-3,492,294 | $-108,714 | $10,105,349 |
| Working Capital | $46,900,426 | $-697,554 | $-1,724,103 | $10,367,955 |
| Total Capitalization | $41,463,045 | $-4,703,695 | $-1,320,177 | $9,029,591 |
| Additional Paid In Capital | $18,724,092 | $17,288,430 | - | - |
| Capital Stock | $99,128,292 | $39,760,349 | $40,258,943 | $40,011,776 |
| Common Stock | $99,128,230 | $39,760,287 | $40,258,943 | $40,011,714 |
| Preferred Stock | $62 | $62 | $62 | $62 |
| Current Deferred Revenue | $0 | $10,413 | $0 | - |
| Current Accrued Expenses | $1,566,613 | $918,564 | $278,664 | $271,858 |
| Net PPE | $27,077 | $1,721 | $3,824 | $13,001 |
| Accumulated Depreciation | $-11,994 | $-10,649 | - | - |
| Gross PPE | $39,071 | $12,370 | $3,824 | $13,001 |
| Construction In Progress | $18,000 | $0 | - | - |
| Other Properties | $21,071 | $12,370 | $3,824 | $13,001 |
| Work In Process | $615,133 | $0 | - | - |
| Raw Materials | $0 | $0 | - | - |
| Pensionand Other Post Retirement Benefit Plans Current | - | $791,280 | $550,660 | $0 |
| Dueto Related Parties Current | - | - | - | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-7,782,355 | $-8,799,565 | $-9,246,526 | $-9,943,004 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-7,755,654 | $-8,799,565 | $-9,241,650 | $-9,879,338 |
| Cash Flow From Continuing Operating Activities | $-7,755,654 | $-8,799,565 | $-9,241,650 | $-9,972,049 |
| Operating Gains Losses | $3,164,707 | $4,085,284 | $-1,823,444 | $6,056,712 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-26,701 | - | $-4,876 | $-63,666 |
| Investing Cash Flow | $-26,701 | $0 | $-4,876 | $459,375 |
| Cash Flow From Continuing Investing Activities | $-26,701 | $0 | $-4,876 | $459,375 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $56,541,384 | $9,223,587 | $0 | $13,651,183 |
| Financing Cash Flow | $54,851,864 | $8,230,015 | $24,785 | $14,878,245 |
| Cash Flow From Continuing Financing Activities | $54,851,864 | $8,230,015 | $24,785 | $14,878,245 |
| Net Other Financing Charges | $-6,236,320 | $-965,572 | - | $-1,195,463 |
| Net Common Stock Issuance | $56,541,384 | $9,223,587 | $0 | $13,651,183 |
| Common Stock Issuance | $56,541,384 | $9,223,587 | $0 | $13,651,183 |
| Cash Dividends Paid | - | $0 | $0 | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-300,000 | $-55,000 | $0 | - |
| Issuance Of Debt | $4,545,000 | $0 | - | $0 |
| Interest Paid Supplemental Data | $37,754 | $59,777 | $16,000 | - |
| End Cash Position | $48,564,082 | $1,494,573 | $2,083,696 | $11,301,793 |
| Beginning Cash Position | $1,494,573 | $2,083,696 | $11,301,793 | $5,926,350 |
| Effect Of Exchange Rate Changes | $0 | $-19,573 | $3,644 | $-82,839 |
| Changes In Cash | $47,069,509 | $-569,550 | $-9,221,741 | $5,458,282 |
| Proceeds From Stock Option Exercised | $301,800 | $27,000 | $40,785 | $2,446,525 |
| Net Issuance Payments Of Debt | $4,245,000 | $-55,000 | $0 | $0 |
| Net Long Term Debt Issuance | $4,245,000 | $-55,000 | $0 | $0 |
| Long Term Debt Payments | $-300,000 | $-55,000 | $0 | - |
| Long Term Debt Issuance | $4,545,000 | $0 | - | $0 |
| Net PPE Purchase And Sale | $-26,701 | $0 | $-4,876 | $-13,666 |
| Purchase Of PPE | $-26,701 | $0 | $-4,876 | $-13,666 |
| Change In Working Capital | $-241,679 | $-1,568,535 | $2,730,088 | $-288,959 |
| Change In Payables And Accrued Expense | $1,045,172 | $-1,451,264 | $2,110,301 | $239,509 |
| Change In Payable | $1,045,172 | $-1,451,264 | $2,110,301 | $239,509 |
| Change In Account Payable | $1,045,172 | $-1,451,264 | $2,110,301 | $239,509 |
| Change In Prepaid Assets | $-671,718 | $-117,271 | $619,787 | $-528,468 |
| Change In Inventory | $-615,133 | $0 | - | - |
| Other Non Cash Items | $2,802,998 | $-6,720 | $168,168 | $2,015,116 |
| Stock Based Compensation | $979,799 | $2,369,585 | $1,701,807 | $1,792,932 |
| Provisionand Write Offof Assets | $55,000 | $0 | - | - |
| Asset Impairment Charge | $39,166 | $0 | $5,506 | $0 |
| Depreciation Amortization Depletion | $81,220 | $84,479 | $90,923 | $89,877 |
| Depreciation And Amortization | $81,220 | $84,479 | $90,923 | $89,877 |
| Gain Loss On Investment Securities | $3,164,707 | $4,085,284 | $-1,823,444 | $6,056,712 |
| Net Income From Continuing Operations | $-14,636,865 | $-13,763,658 | $-12,114,698 | $-19,545,016 |
| Income Tax Paid Supplemental Data | - | $0 | $0 | - |
| Interest Paid Cff | - | $-70,777 | $-16,000 | $-24,000 |
| Amortization Cash Flow | - | $82,376 | $82,376 | $82,375 |
| Amortization Of Intangibles | - | $82,376 | $82,376 | $82,375 |
| Depreciation | - | $2,103 | $8,547 | $7,502 |
| Net Business Purchase And Sale | - | - | $0 | $523,041 |
| Sale Of Business | - | - | $0 | $523,041 |
| Net Intangibles Purchase And Sale | - | - | $0 | $-50,000 |
| Purchase Of Intangibles | - | - | $0 | $-50,000 |
| Change In Tax Payable | - | - | - | $0 |
| Change In Income Tax Payable | - | - | - | $0 |
| Change In Receivables | - | - | - | $0 |